Advisory Board
Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board
American Conference Institute’s Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.
Ali I. Ahmed
Senior Vice President, Biosimilars
Fresenius Kabi USA, LLC
Larry Coury
VP, Associate General Counsel
Regeneron Pharmaceuticals
Neal Dahiya
Head of Litigation
Genentech
Henry Gu
SVP, Head of IP
Zentalis Pharmaceuticals
Brian McCormick
Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy
Teva Pharmaceuticals
Mira A. Mulvaney
Associate VP – Assistant General Patent Counsel, IP Litigation
Eli Lilly and Company
Sonia Tadjalli Oskouei
Vice President, Biosimilars and Specialty
Sandoz, Inc.
Chuck Sholtz
Vice President, Intellectual Property
Legal Department
Nutcracker Therapeutics, Inc.
